Bio-Techne Signs Exclusive License Agreement with Multiclonal Therapeutics for Adult “Ground-state” Stem Cell Technology
MINNEAPOLIS, Minnesota (March 7, 2017)- Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the research reagent field intended for cloning, propagating, and differentiating adult “ground-state” stem cells from healthy and diseased epithelial tissues. Working together, Bio-Techne and MCT will transition this breakthrough technology into... Read more